Investors
New strategy and clear focus
- Fresenius has hit RESET and is now moving towards #FutureFresenius with a simplified structure, sharper focus and acceleration of performance
- Intention to deconsolidate Fresenius Medical Care by changing the legal form of FMC to a German Stock Corporation (“Aktiengesellschaft”) in simplified governance
- Focus on Operating Companies Fresenius Kabi and Fresenius Helios
- Active portfolio management for assets where Fresenius lacks best ownership
- New, more rigorous Fresenius Financial Framework with ambitious segment margin bands
- ~€1bn annual structural productivity improvement by 2025
“We are keeping a quick and consistent pace in implementing our #FutureFresenius program. And the effects are becoming tangible. Our Operating Companies, Fresenius Helios and Fresenius Kabi, have top market positions, and are bringing innovations to patients every day. Both delivered solid second quarter results, including stronger than expected revenue growth. Both are within their respective margin bands, which we established earlier this year as part of our new financial framework...”
Michael Sen, Chairman of the Management Board
Non-financial and Sustainability Reporting
We are committed to being a socially and environmentally responsible corporate player in the global healthcare market. We have the ambition to shape future healthcare and build a sound base for sustainable growth.
News
-
Fresenius appoints Robert Möller to the Management Board
![]()
Fresenius appoints Robert Möller to the Management Board
The Supervisory Board of Fresenius Management SE has appointed Robert Möller (56) to the Management Board with immediate effect. At the same time, he will take over as Chairman of the Management Board of Helios Health GmbH. He succeeds Dr. Francesco de Meo (59), who will leave the company.
September 08, 2023 · Fresenius
-
Brief News
Fresenius Kabi and Formycon secure U.S. License Date for Ustekinumab biosimilar candidate
Fresenius Kabi and Formycon have entered into a settlement agreement with Johnson & Johnson concerning FYB202, a proposed Ustekinumab biosimilar in the United States. Subject to regulatory approval, the settlement grants an entry date for FYB202 in the United States no later than April 15, 2025. FYB202 is an Ustekinumab biosimilar candidate that references Johnson & Johnson’s Stelara®*, a human monoclonal antibody for the treatment of immune-mediated disorders. * Stelara® is a registered trademark of Johnson & Johnson
August 07, 2023 · Fresenius Kabi
-
Fresenius announces changes in the Management Board
![]()
Fresenius announces changes in the Management Board
Dr. Ernst Wastler will leave the Fresenius Management Board upon reaching retirement age on July 18, 2023 Changes and rejuvenation in the Management team of the Fresenius Vamed business segment Strengthened control function through new appointments in the reduced VAMED Supervisory Board and the establishment of an Audit Committee Following successful deconsolidation, Fresenius Medical Care will also no longer be represented on the Fresenius Board in future The composition of the Board reflects realignment through #FutureFresenius The healthcare group Fresenius will have a revised Management team going forward. Dr. Ernst Wastler, previously responsible for Fresenius Vamed, will retire as Chairman of the VAMED Management Board and consequently from the Fresenius Management Board upon reaching retirement age on July 18, 2023. Dr. Klaus Schuster and Frank-Michael Frede will be appointed to the VAMED Management Board. Dr. Klaus Schuster will assume the new role of Spokesman of the VAMED Management Board but will not be represented on the Fresenius Management Board. Dr. Michael Moser, a new member of the Fresenius Management Board, will be responsible for Fresenius Vamed within the Fresenius Board. Following the successful deconsolidation of Fresenius Medical Care, Helen Giza will also step down from the Fresenius Management Board. The #FutureFresenius strategy, with its realignment of business segments into operating and investment companies, is also reflected in the composition of the Fresenius Management Board. "I would like to thank Dr. Wastler for his many years of highly dedicated work on the Fresenius Board," said Wolfgang Kirsch, Chairman of the Supervisory Board of Fresenius. "The leaner Fresenius Board in the future also takes into account the changes on the path to #FutureFresenius that Michael Sen and the Management Board team are successfully and consistently driving forward." Dr. Klaus Schuster joined VAMED Management and Service GmbH as Chief Operating Officer (COO) in 2020. Schuster is a medical doctor and worked as a physician at Landesklinikum St. Pölten for ten years. He studied and obtained his doctorate at the Medical University of Vienna and holds an MBA in Health Care Administration from Danube University Krems. Also appointed to the VAMED Board as of July 1, 2023, is Frank-Michael Frede, CEO of VAMED Deutschland Holding since 2022. Gottfried Koos' (67) tenure on the VAMED Board will end on June 30, 2023. The four-member VAMED Board will continue to include the two current members, Andrea Raffaseder and Andreas Wortmann. Andreas Wortmann, Chief Financial Officer, will additionally take on the newly created role of Chief Transformation Officer. Strengthened control function The control function of the VAMED Supervisory Board will be strengthened. Firstly, it will be reduced from eight to six members. Commercial Councillor Karl Samstag, previously Deputy Chairman of the VAMED AG Supervisory Board and retired CEO of Austria Creditanstalt AG, as well as Dr. Robert Hink, former Secretary General of the Austrian Association of Municipalities, will resign from their positions with effect from the date of the next ordinary Supervisory Board meeting on July 12, 2023. Dr. Dieter Schenk, Deputy Chairman of the Supervisory Board of Fresenius Management SE, will continue to lead the VAMED Supervisory Board. Sara Hennicken, CFO of Fresenius and a member of the VAMED Supervisory Board since December 2022, will remain a member of this Board and is due to be elected Deputy Chairman. Andreas Schmidradner, Advisor to the Management Board of B&C Industrieholding GmbH, will also continue to be a member of the Supervisory Board. Dr. Michael Moser, a future member of the Fresenius Management Board, was newly elected to the VAMED Supervisory Board with effect from July 12, 2023. Together with two employee representatives, Sara Hennicken, Dr. Dieter Schenk, Andreas Schmidradner and Dr. Michael Moser will form the six-member VAMED Supervisory Board going forward. Additionally, an Audit Committee consisting of Sara Hennicken as Chair, Michael Moser as Deputy Chair, and potentially one employee representative will be established.
June 28, 2023 · Fresenius
-
Brief News
Fresenius Kabi expands its critical care portfolio in the U.S.
Fresenius Kabi expands its portfolio of critical care medicines by launching Vasopressin Injection, USP, a generic equivalent to Vasostrict®* in the U.S. Fresenius Kabi Vasopressin is indicated to increase blood pressure in adults with vasodilatory shock who remain hypotensive despite fluids and catecholamines. * Vasostrict® is a registered trademark of Par Pharmaceutical.
June 14, 2023 · Fresenius Kabi
-
Fresenius places sustainable Schuldschein loan of 850 million euros
![]()
Fresenius places sustainable Schuldschein loan of 850 million euros
Fresenius places sustainable Schuldschein loan of 850 million euros
May 22, 2023 · Fresenius
-
Fresenius executing on #FutureFresenius: Strong performance of Operating Companies in Q1/23 and structural simplification on track
![]()
Fresenius executing on #FutureFresenius: Strong performance of Operating Companies in Q1/23 and structural simplification on track
“With a simplified Group structure, improved performance, and a clear focus, Fresenius’s course is set. Productivity measures are gaining traction and we’ve started the new year with good growth momentum,” said Michael Sen, Fresenius CEO.
May 09, 2023 · Fresenius
